Table 5 Reported adverse events other than delayed haemolysis in patients treated with a primary regimen of quinine and of patients treated with a primary regimen of artesunate
Primary treatment | Quinine | Artesunate |
|---|---|---|
n = 31 | n = 5 | |
Any adverse event | 22 (71%) | 3 (60%) |
Hypoglycaemia (<50 mg/dl) | 10 (32%) | 0 (0%) |
Hearing disturbances | 12 (38%) | 0 (0%) |
Visual disturbances | 1 (3%) | 0 (0%) |
Hepatotoxicity | 1 (3%)* | 0 (0%) |
Prolongation of the QTc-interval (>500 ms) | 3 (10%) | 0 (0%) |
Acute renal failure | 8 (26%) | 3 (60%) |
Other** | 2 (6%) | 0 (0%) |